Skin cell therapy for the long term treatment of alopecia areata
Results show the injection of IDO-producing skin cell therapy suppresses the autoimmune response, preventing the progression of alopecia areata. Eighty percent of control mice acquired alopecia areata while none of the IDO cell therapy group was affected. This data was used to apply for a grant from the Canadian Institute of Health Research to conduct more mechanistic studies and eventually a pilot clinical trial. A grant of $100,000 for two years was received.
To investigate the potential for cells that produce the enzyme IDO to inhibit inflammation and hair loss in an alopecia areata mouse model.